GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

Impact · against what's priced in

GSK's plan to double its oncology pipeline via M&A is a positive long-term growth signal, but the impact is muted as the market has already anticipated the company's aggressive dealmaking strategy. The expected increase in R&D spending for 2027 is a known trade-off for this expansion.

Scored by the NIS engine · methodology.

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

biotech▲6%
cancer drugs
oncology
pharma
pipeline
uk

Top 1 mover · tap to explore

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

What matters in this story

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

What matters in this story

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Track these names every morning.

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy

Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

What matters in this story

Next reads from the same story arc

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

What matters in this story

Next reads from the same story arc

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Track these names every morning.

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy

Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters